July 08, 2026 a 05:00 pm
AMGN: Analysts Ratings - Amgen Inc.
Amgen Inc., a stalwart in the biotechnology sector, demonstrates a diversified product portfolio addressing critical therapeutic areas. Recent analyst ratings reflect a moderate confidence in the company’s near-term outlook, with a significant portion of ratings leaning towards 'Hold' and 'Buy'. This suggests a balanced market sentiment, indicating potential for stability with modest growth. Analysts remain cautious but optimistic about Amgen's ability to maintain its foothold amidst competitive pressures and evolving healthcare needs.
Historical Stock Grades
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 10 | |
| Hold | 17 | |
| Sell | 2 | |
| Strong Sell | 1 |
Sentiment Development
- The rating trends for Amgen Inc. over the recent months show a slight decline in 'Strong Buy' recommendations, while 'Hold' ratings have seen a noticeable increase, indicating a shift towards more conservative analyses.
- The total number of ratings has remained relatively stable, suggesting consistent analyst coverage and interest in the company.
- Hold recommendations have seen growth, reflecting a cautious sentiment amid potential market volatility and company-specific developments.
Percentage Trends
The percentage distribution of analyst ratings highlights a recent gravitation towards more neutral positions with 'Hold' steadily increasing, making up about 50% of the total recommendations.
- A decline in strong buy sentiments suggests a note of caution, as analysts appear focused on risk management.
- 'Buy' ratings remaining stable, though slightly lower than earlier periods, points towards a hold-steady approach pending further positive corporate catalysts.
- Notable decrease in 'Strong Buy' percentages reflects tempered enthusiasm compared to the previous year.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-07-06 | Neutral | Neutral | Cantor Fitzgerald |
| 2026-06-16 | Neutral | Neutral | Mizuho |
| 2026-06-10 | Equal Weight | Equal Weight | Morgan Stanley |
| 2026-05-14 | Overweight | Overweight | Piper Sandler |
| 2026-05-04 | Neutral | Neutral | Guggenheim |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-12 | Hold | Buy | Freedom Broker |
| 2026-01-20 | Market Perform | Outperform | Bernstein |
| 2024-10-14 | Hold | Buy | Truist Securities |
| 2024-08-07 | Equal Weight | Overweight | Wells Fargo |
| 2024-05-03 | Outperform | Market Perform | William Blair |
Interpretation
The current sentiment towards Amgen Inc. suggests a market perception of steady performance with limited upside potential in the short term. The prevalence of 'Hold' ratings signifies caution among analysts, reflecting a wait-and-see approach. There is an implied stability in the company, though uncertainty about substantial near-term gains persists. The analyst consensus does not indicate significant enthusiasm but shows a stable outlook that may appeal to risk-averse investors.
Conclusion
Amgen Inc.'s current analyst ratings depict a stable yet cautious sentiment. The decline in 'Strong Buy' ratings over the past year signals a need for strategic operational advancements to reignite investor excitement. Despite this, the stability in 'Hold' and 'Buy' categories suggests confidence in the company's ability to maintain its market position amidst industry pressures. Given the existing product lineup and strategic partnerships, opportunities for growth through innovation and market expansion continue to exist. Therefore, while risks involve competitive dynamics and regulatory challenges, Amgen's foundations remain robust, providing a steady investment profile.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years